Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 307Pancreatic Neoplasms 207Stomach Neoplasms 161Carcinoma, Hepatocellular 160Colonic Neoplasms 115Rectal Neoplasms 104Esophageal Neoplasms 92Carcinoma, Non-Small-Cell Lung 91Breast Neoplasms 76Neoplasms 67Liver Neoplasms 62Ovarian Neoplasms 60Melanoma 51Neoplasm Metastasis 50Cholangiocarcinoma 49Lung Neoplasms 48Squamous Cell Carcinoma of Head and Neck 37Esophageal Squamous Cell Carcinoma 37Gastrointestinal Neoplasms 36Carcinoma, Renal Cell 35Prostatic Neoplasms 33Uterine Cervical Neoplasms 32Sarcoma 32Endometrial Neoplasms 32Biliary Tract Neoplasms 31Anus Neoplasms 30Head and Neck Neoplasms 27Urinary Bladder Neoplasms 22Triple Negative Breast Neoplasms 21Adenocarcinoma Of Esophagus 21

Interventions

lenvatinib 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced Gastric or Gastroesophageal Junction Adenocarcinoma × Gastrointestinal × Clear all
NCT05585580 2026-05-26

Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
59 enrolled
Gastrointestinal

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡